GGrantIndex
← Leaderboards

Paul Richard Territo

Indiana University Indianapolis

Google Scholar ↗PubMed ↗ORCID ↗
$22,416,914
Attributed
$32,017,368
Total exposure
12
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $18.6M · FY2016–25
$20M$15M$10M$5M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$107,303,333 · 13

By mechanism

U54$94,441,562 · 6
U01$4,141,255 · 1
R01$3,236,184 · 1
RF1$3,109,079 · 1
R21$1,582,755 · 3
R56$792,498 · 1

Top collaborators

Others in their field

Top investigators on “Alzheimer&Apos”

Research focus

Alzheimer&AposMouse ModelPreventUniversitiesS DiseaseS Disease ModelCommunitiesNovel TherapeuticsLaboratoriesPhenotypePre-ClinicalInsightPreclinical TestingDisease ModelClinical TrialsAnimal ModelNeuroimagingDementiaIndianaFundingBiological MarkersNerve DegenerationBiologicalDrug Testing

Grant awards (57)

IU/JAX/PITT MODEL-AD Center$9,833,325
U54 · FY2025 · AG
Pre-Clinical Testing Core$2,120,992
U54 · FY2025 · AG · contact PI
Leveraging novel mouse models to investigate toxic metal exposures on brain aging and Alzheimer's disease$2,018,294
U01 · FY2025 · AG
IU/JAX/PITT MODEL-AD Center$9,833,325
U54 · FY2024 · AG
Modeling the role of age at traumatic brain injury in the development of Alzheimer's Disease and related dementias$3,109,079
RF1 · FY2024 · NS
Leveraging novel mouse models to investigate toxic metal exposures on brain aging and Alzheimer's disease$2,122,961
U01 · FY2024 · AG
Pre-Clinical Testing Core$2,120,993
U54 · FY2024 · AG · contact PI
Targeting P2RX7 Signaling as a Treatment for ADRD$792,498
R56 · FY2024 · AG · contact PI
IU/JAX/PITT MODEL-AD Center: Prophylactic Treatment of Long acting GM-CSF (BBT-007) in B6.hAβsaa mice$397,063
U54 · FY2024 · AG
Targeting P2RX7 Signaling as a Biomarker for ADRD$248,796
R21 · FY2024 · AG · contact PI
IU/JAX/PITT MODEL-AD Center$9,833,325
U54 · FY2023 · AG
Pre-Clinical Testing Core$2,104,994
U54 · FY2023 · AG · contact PI
IU/JAX/PITT MODEL-AD Center: Toxicant Exposure Supplement$442,125
U54 · FY2023 · AG
Targeting P2RX7 Signaling as a Biomarker for ADRD$222,816
R21 · FY2023 · AG · contact PI
IU/JAX/PITT MODEL-AD Center$9,790,785
U54 · FY2022 · AG
Pre-Clinical Testing Core$2,096,019
U54 · FY2022 · AG · contact PI
Modulation of TNFα as a Treatment for Alzheimer's Disease and Related Dementia$469,306
R21 · FY2022 · AG · contact PI
The Pathogenic Role of Pb in Cerebral Amyloid Angiopathy and AD$197,848
R21 · FY2022 · AG
The Pathogenic Role of Pb in Cerebral Amyloid Angiopathy and AD Supplement$192,394
R21 · FY2022 · AG
The IU/JAX Alzheimer's Disease Precision Models Center$5,000,000
U54 · FY2021 · AG
Project-002$1,848,922
U54 · FY2021 · AG
Pre-Clinical Testing Core$1,656,121
U54 · FY2021 · AG · contact PI
Core-003$1,136,511
U54 · FY2021 · AG
The IU/JAX Alzheimer's Disease Precision Models Center$6,158,485
U54 · FY2020 · AG
Pre-Clinical Testing Core$1,430,214
U54 · FY2020 · AG · contact PI
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.$600,621
R01 · FY2020 · CA
IU/JAX/Pitt MODEL-AD: Deep Phenotyping Proteomics Year 1$410,578
U54 · FY2020 · AG
IU/JAX/Pitt MODEL-AD: Deep Phenotyping Metabolomics Year 1$406,304
U54 · FY2020 · AG
IU/JAX/Pitt MODEL-AD: Murinizing Aducanumab$396,250
U54 · FY2020 · AG
IU/JAX/PITT MODEL-AD Center: PTC Hardware$389,118
U54 · FY2020 · AG
The Pathogenic Role of Pb in Cerebral Amyloid Angiopathy and AD$251,595
R21 · FY2020 · AG
The IU/JAX Alzheimer's Disease Precision Models Center$5,000,000
U54 · FY2019 · AG
Pre-Clinical Testing Core$1,160,721
U54 · FY2019 · AG · contact PI
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.$604,910
R01 · FY2019 · CA
The IU/JAX Alzheimer's Disease Precision Models Center: Aging$475,532
U54 · FY2019 · AG
The IU/JAX Alzheimer's Disease Precision Models Center: Diet$336,657
U54 · FY2019 · AG
The IU/JAX Alzheimer's Disease Precision Models Center: Electrophysiology$222,955
U54 · FY2019 · AG
The IU/JAX Alzheimer's Disease Precision Models Center: Microbiome$189,547
U54 · FY2019 · AG
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.$20,000
R01 · FY2019 · CA
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.$15,365
R01 · FY2019 · CA
The IU/JAX Alzheimer's Disease Precision Models Center$5,000,000
U54 · FY2018 · AG
Pre-Clinical Testing Core$1,160,721
U54 · FY2018 · AG · contact PI
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.$630,724
R01 · FY2018 · CA
The IU/JAX Alzheimer's Disease Precision Models Center: Genetic Diversity$344,290
U54 · FY2018 · AG
The IU/JAX Alzheimer's Disease Precision Models Center: Nanostring$229,527
U54 · FY2018 · AG
The IU/JAX Alzheimer's Disease Precision Models Center: Drug Selection Criteria$124,395
U54 · FY2018 · AG
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.$52,355
R01 · FY2018 · CA
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.$20,000
R01 · FY2018 · CA
The IU/JAX Alzheimer's Disease Precision Models Center$5,000,000
U54 · FY2017 · AG
Pre-Clinical Testing Core$1,160,721
U54 · FY2017 · AG · contact PI
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.$637,172
R01 · FY2017 · CA
The IU/JAX Alzheimer's Disease Precision Models Center: Metabolomics$176,506
U54 · FY2017 · AG
The IU/JAX Alzheimer's Disease Precision Models Center: Rat F344$155,799
U54 · FY2017 · AG
The IU/JAX Alzheimer's Disease Precision Models Center: PTC Supplement$140,074
U54 · FY2017 · AG
The IU/JAX Alzheimer's Disease Precision Models Center$5,000,000
U54 · FY2016 · AG
Pre-Clinical Testing Core$1,158,668
U54 · FY2016 · AG · contact PI
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.$655,037
R01 · FY2016 · CA